United States connected drug delivery devices market is expected to register an impressive CAGR in the forecast years. The market showed a consistent growth in the historical years from 2018-2022, on account of increase in awareness among consumers regarding the use of self-administrated and connected drug therapy. Rise in cost for in-patient stay at healthcare facilities along with high demand for advanced drug delivery solutions is expected to fuel the market demand. Improvement in quality of patient care and compliance and the changing healthcare infrastructure are expected to boost the United States connected drug delivery devices market growth.
Connected sensors have convenient integration with the existing delivery devices and thus they dominate the market. The segment is anticipated to dominate the United States connected drug delivery devices market in next five years. Connected sensors do not interfere with working of delivery devices and are reusable even if the delivery device is disposed. Moreover, increasing cases of chronic respiratory diseases, chronic obtrusive pulmonary disease are expected to boost the demand for integrated connected drug delivery devices in the future. The smart wireless electronic systems developed for the delivery of desired drug commonly known as connected drug delivery devices results in patient monitoring and counselling the patients with conditions such as asthma, diabetes, hepatitis C, hypertension, tuberculosis, Chronic Obstructive Pulmonary Diseases (COPD), etc.
Additionally, the rise in initiatives and campaigns by healthcare facilities and top authorities to promote the benefits of taking prescribed drugs at the right time and on time to ensure that patients receive effective treatment is anticipated to support the growth of the connected drug delivery devices market. Also, the awareness regarding the benefits of connected system over the traditional drug delivery system with improved patient response is expected to accelerate the growth of the United States connected drug delivery devices market.
Rise in Prevalence of Chronic Diseases
Connected drug delivery systems support the doctors to keep the track of their patients in determining the effectiveness of prescribed treatments and to adjust the patient's care as required. For instance, for people with chronic diseases such as diabetes and asthma, connected drug delivery devices can be helpful for self-medication management. According to Asthma and Allergy Foundation of America, in United States, about 20 million adults below and above age of 18 years have asthma in which around 9.8% of female adults have asthma, compared to 6.1% of male adults. These factors are anticipated to boost the growth of United States connected drug delivery devices market in the forecast years.
Increasing R&D Activities
Rapid advancements in research and development (R&D) for developing drug delivering devices for the treatment of infectious/chronic diseases are contributing to the market growth
Growing Awareness Amongst Patient to Boost Medication
Market Segmentation
The United States connected drug delivery devices market is segmented by product type, technology, application, end user, company and regional distribution. Based on product type, the market is further fragmented into connected sensors, and integrated connected devices. Based on technology, the market is further fragmented into bluetooth, near field communication, and others. Based on application, the market is further fragmented into asthma & COPD, diabetes, and others. Based on end user, the market is segmented into healthcare providers and homecare.
Company Profiles
Abbott Laboratories, Inc., F. Hoffmann-La Roche Ltd. (USA),
Attribute | Details |
Base Year | 2022 |
Historical Years | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered | Product Type Technology Application End User |
Region Covered | North-East, Mid-West, South, West |
Key Companies Profiled | Abbott Laboratories, Inc., F. Hoffmann-La Roche Ltd. (USA), Reciprocal Labs Corporation (Propeller Health), Teva USA, Merck & Co., West Pharmaceutical Services, Inc., Molex LLC (Phillips Medisize), Cohero Health, Inc., Becton, Dickinson, and Company, Unilife Corporation. |
Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |